EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors

Table 1 Chemotherapies, immunotherapies, and targeted therapies for metastatic NSCLC

Type of Therapy	Agents/Agent combinations
Traditional Chemotherapies
Platinum monotherapy	Carboplatin, Cisplatin
Platinum doublet therapy
With cisplatin	Docetaxel, Etoposide, Gemcitabine, Irinotecan, Paclitaxel, Pemetrexed, Vinorelbine
With carboplatin	Docetaxel, Gemcitabine, Paclitaxel, Pemetrexed, Vinorelbine
Non-platinum based combination therapies	Gemcitabine/Docetaxel, Gemcitabine/Paclitaxel, Gemcitabine/Vinorelbine, Paclitaxel/Vinorelbine, Pemetrexed/Gemcitabine
Maintenance therapy	Docetaxel, Gemcitabine, Pemetrexed
Immunotherapies	Atezolizumab, Nivolumab, Pembrolizumab
Targeted Therapies
ALK inhibitors	Alectinib, Brigatinib, Ceritinib, Crizotinib
Angiogenesis inhibitors	Bevacizumab, Ramucirumab
BRAF inhibitor	Vemurafenib
CDK4/6 inhibitor	Palbociclib
EGFR monoclonal antibody inhibitor	Cetuximab, Necitumumab
EGFR tyrosine kinase inhibitors	Afatinib, Erlotinib, Gefitinib, Osimertinib
MEK inhibitor	Trametinib
Other monoclonal antibody inhibitors	Ipilimumab, Trastuzumab

ALK anaplastic lymphoma kinase, BRAF Raf isoform B, CDK cyclin dependent kinase, EGFR epidermal growth factor receptor, MEK mitogen activated protein kinase kinase

ISSN: 1471-2407